HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd

被引：0

作者：

Singer, Christian Fridolin ^{[1
,2
,3
]}

Jahn, Stephan Wenzel ^{[4
]}

Hlauschek, Dominik ^{[3
]}

Heber, Ulrike Maria ^{[2
,5
]}

Mang-Manger, Charlotte ^{[2
]}

Egle, Daniel ^{[3
,6
]}

Balic, Marija ^{[3
,7
,8
]}

Pichler, Angelika ^{[9
]}

Pfeiler, Georg ^{[1
,3
]}

Kacerovsky-Strobl, Stephanie ^{[3
]}

Suppan, Christoph ^{[3
,7
]}

Ritter, Magdalena ^{[6
]}

Petru, Edgar ^{[10
]}

Greil, Richard ^{[3
,11
]}

Bago-Horvath, Zsuzsanna ^{[2
,3
,5
]}

Deutschmann, Christine ^{[1
]}

Steger, Guenther Georg ^{[2
,3
]}

Seifert, Michael ^{[1
,3
]}

Fitzal, Florian ^{[3
,12
,13
]}

Bartsch, Rupert ^{[2
,3
]}

Santhanagopal, Anu ^{[14
]}

Machacek-Link, Jana ^{[3
]}

Sellami, Dalila ^{[15
]}

Schwarz, Magdalena ^{[3
]}

Fesl, Christian ^{[3
]}

Soelkner, Lidija ^{[3
]}

Esker, Stephen ^{[15
]}

Filipits, Martin ^{[2
,3
,16
]}

Gnant, Michael ^{[2
,3
]}

机构：

[1] Med Univ Vienna, Dept Gynecol & Gynecol Oncol, Vienna, Austria

[2] Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria

[3] Austrian Breast & Colorectal Canc Study Grp ABCSG, Vienna, Austria

[4] Med Univ Graz, Diagnost & Res Inst Pathol, Graz, Austria

[5] Med Univ Vienna, Dept Pathol, Vienna, Austria

[6] Med Univ Innsbruck, Dept Obstet & Gynecol, Innsbruck, Austria

[7] Med Univ Graz, Div Clin Oncol, Dept Internal Med, Graz, Austria

[8] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA

[9] LKH Hochsteiermark Leoben, Dept Internal Med Hematol & Internal Oncol, Leoben, Austria

[10] Med Univ Graz, Dept Obstet & Gynecol, Div Gynecol, Graz, Austria

[11] Paracelsus Med Univ Salzburg, Dept Internal Med 3, Salzburg, Austria

[12] Hanusch Hosp, Vienna, Austria

[13] Med Univ Vienna, Dept Gen Surg, Vienna, Austria

[14] Daiichi Sankyo Inc, Global Oncol Med Affairs, Basking Ridge, NJ USA

[15] Daiichi Sankyo Inc, Oncol Clin Dev, Basking Ridge, NJ USA

[16] Med Univ Vienna, Ctr Canc Res, Vienna, Austria

来源：

CANCER COMMUNICATIONS | 2025年

关键词：

D O I：

10.1002/cac2.12657

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：5

共 50 条

[1] Phase 1/2 study of HER3-DXd in HER3-expressing metastatic breast cancer: Subgroup analysis by HER2 expression
Iwata, Hiroji
Krop, Ian E.
Masuda, Norikazu
Mukohara, Toru
Takahashi, Shunji
Nakayama, Takahiro
Inoue, Kenichi
Toyama, Tatsuya
Yamamoto, Yutaka
Alvarez, Ricardo H.
Takahashi, Masato
Osaki, Akihiko
Ohwada, Shoichi
Mostillo, Joseph
Tanaka, Yoshimi
Sternberg, David
Sellami, Dalila
ANNALS OF ONCOLOGY, 2023, 34 : S1379 - S1379
[2] EGFR inhibitor upregulates HER3 expression and enhances the efficacy of HER3 targeting patritumab deruxtecan (HER3-DXd)
Yonesaka, Kimio
Tanizaki, Junko
Maenishi, Osamu
Sakai, Kazuko
Goto, Hiroki
Kobayashi, Maki
Yoshimoto, Ryoto
Otsuka, Eri
Okida, Hiroaki
Funabashi, Masanori
Hashimoto, Yuuri
Hirotani, Kenji
Kagari, Takashi
Nishio, Kazuto
Nakagawa, Kazuhiko
CANCER SCIENCE, 2022, 113 : 896 - 896
[3] Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
Koyama, Kumiko
Ishikawa, Hirokazu
Abe, Manabu
Shiose, Yoshinobu
Ueno, Suguru
Qiu, Yang
Nakamaru, Kenji
Murakami, Masato
PLOS ONE, 2022, 17 (05):
[4] HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers
Drago, Joshua Z.
Pareja, Fresia
Jhaveri, Komal L.
Walsh, Elaine M.
Ku, Geoffrey Yuyat
Maron, Steven Brad
Janjigian, Yelena Y.
Robson, Mark E.
Reis-Filho, Jorge S.
Modi, Shanu
Razavi, Pedram
Chandarlapaty, Sarat
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] Impact of HER2 Expression on trastuzumab deruxtecan(T-DXd) efficacy
Chen, Wanyi
Drago, Joshua
Gupta, Avantika
Liu, Bo
Chandarlapaty, Sarat
CANCER RESEARCH, 2024, 84 (06)
[6] HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive
Campbell, Marcia R.
Moasser, Mark M.
CLINICAL CANCER RESEARCH, 2015, 21 (13) : 2886 - 2888
[7] T-DXd: New Standard for HER2-Low Breast Cancer
Poh, Alissa
CANCER DISCOVERY, 2022, 12 (08) : 1828 - 1828
[8] Antitumor effect of HER3-DXd, an antibody-drug conjugate targeting HER3, in gastric cancer cell lines
Hwang, Hae Min
Kim, So Hyeon
Ham, Sujin
Lee, Minyoung
Noh, Youlim
Kim, Yu-Jin
Lee, Changyun
Kim, Jinyoung
Lee, Dae-Won
Lee, Kyung-Hun
Im, Seock-Ah
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[9] Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
Tarantino, P.
Tolaney, S. M.
Curigliano, G.
ANNALS OF ONCOLOGY, 2023, 34 (10) : 949 - 950
[10] T-DXd Demonstrates Real-World Efficacy in Advanced Breast Cancer With Dynamic HER2 EXPression
Antino, Tar
AMERICAN JOURNAL OF MANAGED CARE, 2024, 30 (02):

← 1 2 3 4 5 →